Key facts
- EXOKĒRYX’s last known valuation is $48.0M (Jan 2025).
- It has raised $26.8M; the latest was Seed Round ($13.0M) in Jan 2025.
- Notable investors include CONNECT (San Diego), Silicon Catalyst, Silicon Catalyst Ventures, Silicon Catalyst Angels, Cove Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for EXOKĒRYX
- ·The full record, as it builds
Funding rounds
No funding rounds for EXOKĒRYX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EXOKĒRYX
Developer of automated tools and tests designed for the isolation and analysis of extracellular vesicles. The company's platform merges semiconductor technology with multi-omics analysis, enabling researchers to achieve the sensitivity and specificity needed to identify diseases at earlier stages.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 32
- Website
- exokeryx.com/
- Ownership
- Privately Held (backing)
EXOKĒRYX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EXOKĒRYX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EXOKĒRYX in its N-PORT filings yet. We sweep new filings monthly.